These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 27313896)

  • 1. Evolving Paradigm of Radiotherapy for High-Risk Prostate Cancer: Current Consensus and Continuing Controversies.
    Juloori A; Shah C; Stephans K; Vassil A; Tendulkar R
    Prostate Cancer; 2016; 2016():2420786. PubMed ID: 27313896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variations in patterns of concurrent androgen deprivation therapy use based on dose escalation with external beam radiotherapy vs. brachytherapy boost for prostate cancer.
    Mohiuddin JJ; Narayan V; Venigalla S; Vapiwala N
    Brachytherapy; 2019; 18(3):322-331. PubMed ID: 30862436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Randomized Phase II Trial of Prostate Boost Irradiation With Stereotactic Body Radiotherapy (SBRT) or Conventional Fractionation (CF) External Beam Radiotherapy (EBRT) in Locally Advanced Prostate Cancer: The PBS Trial (NCT03380806).
    Isfahanian N; Lukka H; Dayes I; Quan K; Schnarr KL; Douvi G; Goldberg M; Wright J; Swaminath A; Chow T; Diamond K; Cutz JC; Kavsak P; Thabane L; Tsakiridis T
    Clin Genitourin Cancer; 2020 Aug; 18(4):e410-e415. PubMed ID: 32265129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic Body Radiotherapy for High-Risk Prostate Cancer: A Systematic Review.
    Foerster R; Zwahlen DR; Buchali A; Tang H; Schroeder C; Windisch P; Vu E; Akbaba S; Bostel T; Sprave T; Zamboglou C; Zilli T; Stelmes JJ; Telkhade T; Murthy V
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33673077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors, efficacy, and toxicity of involved-node stereotactic body radiation therapy for lymph node oligorecurrent prostate cancer : An investigation of 117 pelvic lymph nodes.
    Cozzi S; Botti A; Timon G; Blandino G; Najafi M; Manicone M; Bardoscia L; Ruggieri MP; Ciammella P; Iotti C
    Strahlenther Onkol; 2022 Aug; 198(8):700-709. PubMed ID: 34757443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic body-radiotherapy boost dose of 18 Gy vs 21 Gy in combination with androgen-deprivation therapy and whole-pelvic radiotherapy for intermediate- or high-risk prostate cancer: a study protocol for a randomized controlled, pilot trial.
    Kim YJ; Ahn H; Kim CS; Lee JL; Kim YS
    Trials; 2018 Apr; 19(1):212. PubMed ID: 29609646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brachytherapy boost (BT-boost) or stereotactic body radiation therapy boost (SBRT-boost) for high-risk prostate cancer (HR-PCa).
    Peyraga G; Lizee T; Khalifa J; Blais E; Mauriange-Turpin G; Supiot S; Krhili S; Tremolieres P; Graff-Cailleaud P
    Cancer Radiother; 2021 Jun; 25(4):400-409. PubMed ID: 33478838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer.
    Falchook AD; Basak R; Mohiuddin JJ; Chen RC
    Cancer; 2016 Aug; 122(15):2341-9. PubMed ID: 27191936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts.
    Kishan AU; Steigler A; Denham JW; Zapatero A; Guerrero A; Joseph D; Maldonado X; Wong JK; Stish BJ; Dess RT; Pilar A; Reddy C; Wedde TB; Lilleby WA; Fiano R; Merrick GS; Stock RG; Demanes DJ; Moran BJ; Tran PT; Martin S; Martinez-Monge R; Krauss DJ; Abu-Isa EI; Pisansky TM; Choo CR; Song DY; Greco S; Deville C; McNutt T; DeWeese TL; Ross AE; Ciezki JP; Tilki D; Karnes RJ; Tosoian JJ; Nickols NG; Bhat P; Shabsovich D; Juarez JE; Jiang T; Ma TM; Xiang M; Philipson R; Chang A; Kupelian PA; Rettig MB; Feng FY; Berlin A; Tward JD; Davis BJ; Reiter RE; Steinberg ML; Elashoff D; Boutros PC; Horwitz EM; Tendulkar RD; Spratt DE; Romero T
    JAMA Oncol; 2022 Mar; 8(3):e216871. PubMed ID: 35050303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of accelerated hypofractionated whole pelvis radiation therapy prior to high dose rate brachytherapy or stereotactic body radiation therapy prostate boost.
    Phuong C; Chan JW; Ni L; Wall P; Mohamad O; Wong AC; Hsu IC; Chang AJ
    Radiat Oncol; 2022 Jan; 17(1):12. PubMed ID: 35057827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing Androgen Deprivation Therapy (ADT) integration in prostate cancer: Insights for Stereotactic Body Radiotherapy (SBRT) and brachytherapy modalities.
    Gomez-Iturriaga A; Büchser D; Lopez-Campos F; Maldonado X
    Clin Transl Radiat Oncol; 2024 Mar; 45():100733. PubMed ID: 38322544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.
    Shilkrut M; Merrick GS; McLaughlin PW; Stenmark MH; Abu-Isa E; Vance SM; Sandler HM; Feng FY; Hamstra DA
    Cancer; 2013 Feb; 119(3):681-90. PubMed ID: 22893254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
    Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
    Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. External beam radiation therapy and a low-dose-rate brachytherapy boost without or with androgen deprivation therapy for prostate cancer.
    Strom TJ; Hutchinson SZ; Shrinath K; Cruz AA; Figura NB; Nethers K; Biagioli MC; Fernandez DC; Heysek RV; Wilder RB
    Int Braz J Urol; 2014; 40(4):474-83. PubMed ID: 25251952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcomes for men with high-risk prostate cancer treated definitively with external beam radiotherapy with or without androgen deprivation.
    Nguyen QN; Levy LB; Lee AK; Choi SS; Frank SJ; Pugh TJ; McGuire S; Hoffman K; Kuban DA
    Cancer; 2013 Sep; 119(18):3265-71. PubMed ID: 23798338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of definitive external beam radiation therapy in the treatment of prostate cancer.
    Daly T
    World J Urol; 2020 Mar; 38(3):565-591. PubMed ID: 30850855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early outcomes of high-dose-rate brachytherapy combined with ultra-hypofractionated radiation in higher-risk prostate cancer.
    Gorovets D; Hopkins M; Kollmeier M; Moore A; Goel A; Shasha D; Brennan V; McBride S; Cohen G; Damato AL; Zelefsky MJ
    Brachytherapy; 2021; 20(6):1099-1106. PubMed ID: 34588146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ESTRO-ACROP recommendations for evidence-based use of androgen deprivation therapy in combination with external-beam radiotherapy in prostate cancer.
    Schmidt-Hegemann NS; Zamboglou C; Mason M; Mottet N; Hinnen K; De Meerleer G; Cozzarini C; Maingon P; Henry A; Spahn M; Cornford P; Belka C; Wiegel T
    Radiother Oncol; 2023 Jun; 183():109544. PubMed ID: 36813168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. American Brachytherapy Society Task Group Report: Combination of brachytherapy and external beam radiation for high-risk prostate cancer.
    Spratt DE; Soni PD; McLaughlin PW; Merrick GS; Stock RG; Blasko JC; Zelefsky MJ
    Brachytherapy; 2017; 16(1):1-12. PubMed ID: 27771243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.